On Friday, C4 Therapeutics Inc (NASDAQ: CCCC) was -4.35% drop from the session before settling in for the closing price of $1.61. A 52-week range for CCCC has been $1.09 – $7.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 19.86% over the past five years. When this article was written, the company’s average yearly earnings per share was at -19.20%. With a float of $56.72 million, this company’s outstanding shares have now reached $70.63 million.
Let’s look at the performance matrix of the company that is accounted for 110 employees. In terms of profitability, gross margin is 82.78%, operating margin of -336.15%, and the pretax margin is -295.6%.
C4 Therapeutics Inc (CCCC) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward C4 Therapeutics Inc stocks. The insider ownership of C4 Therapeutics Inc is 20.11%, while institutional ownership is 83.74%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -19.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.33% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
You can see what C4 Therapeutics Inc (CCCC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.64 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
C4 Therapeutics Inc (NASDAQ: CCCC) saw its 5-day average volume 2.09 million, a positive change from its year-to-date volume of 1.48 million. As of the previous 9 days, the stock’s Stochastic %D was 76.41%. Additionally, its Average True Range was 0.18.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 11.22%, which indicates a significant decrease from 69.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 111.53% in the past 14 days, which was higher than the 86.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0172, while its 200-day Moving Average is $4.3944. Nevertheless, the first resistance level for the watch stands at $1.6207 in the near term. At $1.7015, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7668. If the price goes on to break the first support level at $1.4746, it is likely to go to the next support level at $1.4093. The third support level lies at $1.3285 if the price breaches the second support level.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are 71,007K outstanding shares of the company, which has a market capitalization of 109.35 million. As of now, sales total 35,580 K while income totals -105,320 K. Its latest quarter income was 5,180 K while its last quarter net income were -34,570 K.
